# Encorafenib

PHAROS

Encorafenib PHAROS

## PRELIMINARY SCORE

**CURATIVE**

**NON-CURATIVE**

ORR

## ADJUSTMENTS

**Quality of life**

Not qualified for an ESMO-MCBS credit

**Serious and disabling adverse effects**

**Other adjustments**

Encorafenib PHAROS

## SCORE

**CURATIVE**

Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

3

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies
Therapeutic Indication: Encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation - previously treated
Experimental Arm: Encorafenib + Binimetinib
Control Arm: Single arm

© 2024 | **European Society for Medical Oncology** | ESMO - MCBS 1.1 | All rights reserved worldwide.